Overview

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

Status:
Terminated

Trial end date:
2019-11-20

Target enrollment:

Participant gender:

Summary

The purpose of this study was to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in participants with progressive supranuclear palsy (PSP).

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Treatments:

Tilavonemab